Key result
HFmrEF and HFpEF are linked to ~50% lower odds of SGLT2i prescription vs HFrEF.
Why the study?
This study aimed to describe the clinical and paraclinical characteristics and pharmacological treatment patterns in outpatients with chronic heart failure at Bach Mai Hospital in 2025.
Cross-Sectional (n=486)
No
In this outpatient chronic heart failure cohort at Bach Mai Hospital, HFpEF was the predominant phenotype, while suboptimal utilization of four-pillar guideline-directed medical therapy in HFrEF (22.5%) and lower SGLT2i use in HFmrEF/HFpEF highlight the need for stronger guideline implementation.
Answers are grounded in this paper and cite their sources.
Suboptimal quadruple therapy rates in HFrEF outpatients signal implementation gaps; leaves open whether targeted strategies boost SGLT2i uptake across phenotypes.
Objective: To describe clinical and paraclinical characteristics and pharmacological treatment in outpatients with chronic heart failure at Bach Mai Hospital in 2025.Participants and Methods: A cross-sectional descriptive study of 486 outpatients with chronic heart failure at the Department of Outpatient Examination, Bach Mai Hospital, from June 2025 to December 2025. Medications were recorded from the prescriptions in use at the time of the survey and grouped according to the European Society of Cardiology guidelines.Results: Mean age was 63.3 ± 12.7 years; NYHA class II accounted for 54.1%, and ischemic heart disease was the most common etiology (38.5%). HFpEF was the predominant phenotype (56.4%). Beta-blockers were used most frequently (64.6%), followed by SGLT2i (56.4%) and MRAs (54.5%). Among 102 patients with HFrEF, 22.5% received all four foundational drug classes. SGLT2i use was highest in HFrEF (68.6%). Patients with HFmrEF and HFpEF were less likely to receive SGLT2i than those with HFrEF (adjusted OR = 0.50; p < 0.05).Conclusion: HFpEF predominated, four-drug therapy remained limited in HFrEF, and differences in SGLT2i use across EF groups support stronger implementation of current guidelines.
No takes yet. Share an insight, caveat, or question.
Hoàng et al. (2026) conducted a cross-sectional in Chronic heart failure (n=486). HFmrEF and HFpEF phenotypes vs. HFrEF phenotype was evaluated on SGLT2 inhibitor prescription use across ejection fraction groups (OR 0.50, p=<0.05). Pharmacological therapy in chronic HF outpatients showed 22.5% quadruple therapy use in HFrEF and lower SGLT2i prescription in HFmrEF/HFpEF vs HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: